Mary Bridge Children's Health Center
Welcome,         Profile    Billing    Logout  
 0 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ibrahim, Kamleh
THRIVE-132, NCT04927247: A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Terminated
3
72
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
11/23
11/23
NCT04469686 / 2019-003596-19: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

Completed
3
200
US
Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo
Cristcot LLC, Cristcot HCA LLC
Ulcerative Proctitis
07/24
09/24
THRIVE-131, NCT04935879: A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

Completed
3
243
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
06/24
06/24
HIBISCUS, NCT04624659: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease

Recruiting
2/3
344
Europe, Canada, US, RoW
Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets
Forma Therapeutics, Inc., Novo Nordisk A/S
Sickle Cell Disease
03/26
04/27
HOPE-KIDS 1, NCT02850406: Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease

Terminated
2
147
Europe, US, RoW
Voxelotor
Pfizer, Pfizer
Sickle Cell Disease
10/23
10/23
Pugh, Julianne
HIBISCUS, NCT04624659: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease

Recruiting
2/3
344
Europe, Canada, US, RoW
Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets
Forma Therapeutics, Inc., Novo Nordisk A/S
Sickle Cell Disease
03/26
04/27
Leblanc, Guillaume
LUNA3, NCT04562766 / 2020-002063-60: Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Recruiting
3
194
Europe, Canada, Japan, US, RoW
Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo
Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc.
Immune Thrombocytopenia
06/25
11/26
HIBISCUS, NCT04624659: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease

Recruiting
2/3
344
Europe, Canada, US, RoW
Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets
Forma Therapeutics, Inc., Novo Nordisk A/S
Sickle Cell Disease
03/26
04/27
NCT05489887: Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Recruiting
2
76
Canada, US
Naxitamab, Danyelza, Ceritinib
Giselle Sholler, Y-mAbs
High-risk Neuroblastoma
09/26
09/33
NMTT, NCT02679144: Neuroblastoma Maintenance Therapy Trial

Recruiting
2
441
Canada, US
Difluoromethylornithine (DFMO), eflornithine
Giselle Sholler, Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
02/28
02/33
NCT04301843: Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Recruiting
2
131
Canada, US
Eflornithine, DFMO, difluoromethylornithine
Giselle Sholler, K C Pharmaceuticals Inc., Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
10/28
10/33
PEDS-PLAN, NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting
2
500
Canada, US
Ceritinib, Zykadia, dasatinib, Sprycel, sorafenib, Nexavar, vorinostat, ZOLINZA, DFMO, Eflornithine, α-difluoromethylornithine
Giselle Sholler, Dell, Inc., Beat NB Cancer Foundation, K C Pharmaceuticals Inc., Team Parker for Life
Neuroblastoma
09/30
09/35
Oikonomou, Georgia
HIBISCUS, NCT04624659: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease

Recruiting
2/3
344
Europe, Canada, US, RoW
Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets
Forma Therapeutics, Inc., Novo Nordisk A/S
Sickle Cell Disease
03/26
04/27

Download Options